Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density

Clifford M. Csizmar, Jacob R. Petersburg, Thomas J. Perry, Lakmal Rozumalski, Benjamin J Hackel, Carston R Wagner

Research output: Contribution to journalArticle

Abstract

Nature uses multivalency to govern many biological processes. The development of macromolecular and cellular therapies has largely been dependent on engineering similar polyvalent interactions to enable effective targeting. Such therapeutics typically utilize high-affinity binding domains that have the propensity to recognize both antigen-overexpressing tumors and normal-expressing tissues, leading to "on-target, off-tumor" toxicities. One strategy to improve these agents' selectivity is to reduce the binding affinity, such that biologically relevant interactions between the therapeutic and target cell will only exist under conditions of high avidity. Preclinical studies have validated this principle of avidity optimization in the context of chimeric antigen receptor (CAR) T cells; however, a rigorous analysis of this approach in the context of soluble multivalent targeting scaffolds has yet to be undertaken. Using a modular protein nanoring capable of displaying ≤8 fibronectin domains with engineered specificity for a model antigen, epithelial cell adhesion molecule (EpCAM), this study demonstrates that binding affinity and ligand valency can be optimized to afford discrimination between EpCAM High (2.8-3.8 × 10 6 antigens/cell) and EpCAM Low (5.2 × 10 4 to 2.2 × 10 5 antigens/cell) tissues both in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)251-261
Number of pages11
JournalJournal of the American Chemical Society
Volume141
Issue number1
DOIs
StatePublished - Jan 9 2019

Fingerprint

Cell Adhesion Molecules
Cell membranes
Antigens
Ligands
Cell Membrane
Cell adhesion
Nanorings
Tissue
Biological Phenomena
Molecules
Neoplasm Antigens
Tumors
T-Cell Antigen Receptor
Fibronectins
Scaffolds
Toxicity
Therapeutics
T-cells
Epithelial Cells
Epithelial Cell Adhesion Molecule

Cite this

Multivalent Ligand Binding to Cell Membrane Antigens : Defining the Interplay of Affinity, Valency, and Expression Density. / Csizmar, Clifford M.; Petersburg, Jacob R.; Perry, Thomas J.; Rozumalski, Lakmal; Hackel, Benjamin J; Wagner, Carston R.

In: Journal of the American Chemical Society, Vol. 141, No. 1, 09.01.2019, p. 251-261.

Research output: Contribution to journalArticle

@article{458e45ddf85b41eea563fe228641acf0,
title = "Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density",
abstract = "Nature uses multivalency to govern many biological processes. The development of macromolecular and cellular therapies has largely been dependent on engineering similar polyvalent interactions to enable effective targeting. Such therapeutics typically utilize high-affinity binding domains that have the propensity to recognize both antigen-overexpressing tumors and normal-expressing tissues, leading to {"}on-target, off-tumor{"} toxicities. One strategy to improve these agents' selectivity is to reduce the binding affinity, such that biologically relevant interactions between the therapeutic and target cell will only exist under conditions of high avidity. Preclinical studies have validated this principle of avidity optimization in the context of chimeric antigen receptor (CAR) T cells; however, a rigorous analysis of this approach in the context of soluble multivalent targeting scaffolds has yet to be undertaken. Using a modular protein nanoring capable of displaying ≤8 fibronectin domains with engineered specificity for a model antigen, epithelial cell adhesion molecule (EpCAM), this study demonstrates that binding affinity and ligand valency can be optimized to afford discrimination between EpCAM High (2.8-3.8 × 10 6 antigens/cell) and EpCAM Low (5.2 × 10 4 to 2.2 × 10 5 antigens/cell) tissues both in vitro and in vivo.",
author = "Csizmar, {Clifford M.} and Petersburg, {Jacob R.} and Perry, {Thomas J.} and Lakmal Rozumalski and Hackel, {Benjamin J} and Wagner, {Carston R}",
year = "2019",
month = "1",
day = "9",
doi = "10.1021/jacs.8b09198",
language = "English (US)",
volume = "141",
pages = "251--261",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Multivalent Ligand Binding to Cell Membrane Antigens

T2 - Defining the Interplay of Affinity, Valency, and Expression Density

AU - Csizmar, Clifford M.

AU - Petersburg, Jacob R.

AU - Perry, Thomas J.

AU - Rozumalski, Lakmal

AU - Hackel, Benjamin J

AU - Wagner, Carston R

PY - 2019/1/9

Y1 - 2019/1/9

N2 - Nature uses multivalency to govern many biological processes. The development of macromolecular and cellular therapies has largely been dependent on engineering similar polyvalent interactions to enable effective targeting. Such therapeutics typically utilize high-affinity binding domains that have the propensity to recognize both antigen-overexpressing tumors and normal-expressing tissues, leading to "on-target, off-tumor" toxicities. One strategy to improve these agents' selectivity is to reduce the binding affinity, such that biologically relevant interactions between the therapeutic and target cell will only exist under conditions of high avidity. Preclinical studies have validated this principle of avidity optimization in the context of chimeric antigen receptor (CAR) T cells; however, a rigorous analysis of this approach in the context of soluble multivalent targeting scaffolds has yet to be undertaken. Using a modular protein nanoring capable of displaying ≤8 fibronectin domains with engineered specificity for a model antigen, epithelial cell adhesion molecule (EpCAM), this study demonstrates that binding affinity and ligand valency can be optimized to afford discrimination between EpCAM High (2.8-3.8 × 10 6 antigens/cell) and EpCAM Low (5.2 × 10 4 to 2.2 × 10 5 antigens/cell) tissues both in vitro and in vivo.

AB - Nature uses multivalency to govern many biological processes. The development of macromolecular and cellular therapies has largely been dependent on engineering similar polyvalent interactions to enable effective targeting. Such therapeutics typically utilize high-affinity binding domains that have the propensity to recognize both antigen-overexpressing tumors and normal-expressing tissues, leading to "on-target, off-tumor" toxicities. One strategy to improve these agents' selectivity is to reduce the binding affinity, such that biologically relevant interactions between the therapeutic and target cell will only exist under conditions of high avidity. Preclinical studies have validated this principle of avidity optimization in the context of chimeric antigen receptor (CAR) T cells; however, a rigorous analysis of this approach in the context of soluble multivalent targeting scaffolds has yet to be undertaken. Using a modular protein nanoring capable of displaying ≤8 fibronectin domains with engineered specificity for a model antigen, epithelial cell adhesion molecule (EpCAM), this study demonstrates that binding affinity and ligand valency can be optimized to afford discrimination between EpCAM High (2.8-3.8 × 10 6 antigens/cell) and EpCAM Low (5.2 × 10 4 to 2.2 × 10 5 antigens/cell) tissues both in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=85059812571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059812571&partnerID=8YFLogxK

U2 - 10.1021/jacs.8b09198

DO - 10.1021/jacs.8b09198

M3 - Article

VL - 141

SP - 251

EP - 261

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 1

ER -